Actionable Activating Oncogenic ERBB2/HER2 Transmembrane and Juxtamembrane Domain Mutations

Deregulated HER2 is a target of many approved cancer drugs. We analyzed 111,176 patient tumors and identified recurrent mutations in HER2 transmembrane domain (TMD) and juxtamembrane domain (JMD) that include G660D, R678Q, E693K, and Q709L. Using a saturation mutagenesis screen and testing of patien...

Full description

Saved in:
Bibliographic Details
Published in:Cancer cell 2018-11, Vol.34 (5), p.792-806.e5
Main Authors: Pahuja, Kanika Bajaj, Nguyen, Thong T., Jaiswal, Bijay S., Prabhash, Kumar, Thaker, Tarjani M., Senger, Kate, Chaudhuri, Subhra, Kljavin, Noelyn M., Antony, Aju, Phalke, Sameer, Kumar, Prasanna, Mravic, Marco, Stawiski, Eric W., Vargas, Derek, Durinck, Steffen, Gupta, Ravi, Khanna-Gupta, Arati, Trabucco, Sally E., Sokol, Ethan S., Hartmaier, Ryan J., Singh, Ashish, Chougule, Anuradha, Trivedi, Vaishakhi, Dutt, Amit, Patil, Vijay, Joshi, Amit, Noronha, Vanita, Ziai, James, Banavali, Sripad D., Ramprasad, Vedam, DeGrado, William F., Bueno, Raphael, Jura, Natalia, Seshagiri, Somasekar
Format: Article
Language:English
Subjects:
anti-HER2 antibodies
ERBB2 activation
ERBB2 structure
ERBB2/HER2
HER2 germline mutation
HER2 kinase inhibitors
HER2 somatic mutation
juxtamembrane (JMD) domain mutation
transmembrane domain (TMD) mutation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!